For research use only. Not for therapeutic Use.
PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development[1].
PA452 inhibits the Troglitazone (TZ)-induced CK13 expression[2].
PA452 (0.01, 0.1, and 1 μM) inhibits RXR in normal human urothelial (NHU) cells[2].
| Catalog Number | I010686 |
| CAS Number | 457657-34-0 |
| Molecular Formula | C26H37N3O3 |
| Purity | ≥95% |
| Reference | [1]. Iwata M, et al. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003 Aug;15(8):1017-25. [2]. Varley CL, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004 May;164(5):1789-98. |
